Table 3.
Baseline Clinical Characteristics of Patients on Insulin Therapya
| Intervention group n = 365 | Control group n = 332 | |
|---|---|---|
| Age | 68.5 ± 7.3 | 68.3 ± 8.8 |
| Female (%) | 157 (42.9) | 145 (43.8) |
| Male (%) | 208 (57.1) | 187 (56.2) |
| HbA1c (SD) | 7.88 (1.38) | 7.80 (1.52) |
| BMI (kg/m2) | 29.2 ± 4.1 | 29.8 ± 4.5 |
| Daily dose of insulin U (SD) | 13.63 (4.43) | 13.53 (4.39) |
| Only insulin therapy (%) | 225 (61.6) | 209 (62.9) |
| Insulin plus oral antidiabetics (%) | 140 (38.3) | 123 (37) |
| Oral antidiabetics (%): | ||
| Metformin | 130 (35.5) | 116 (34.8) |
| Sulfonylureas | 13 (3.5) | 10 (2.9) |
| Glitazones | 0 (0) | 0 (0) |
| DPP-4 inhibitors | 8 (2.1) | 5 (1.4) |
| Two oral antidiabetics (%) | 11 (2.8) | 8 (2.2) |
a
No statistical differences between groups for any item. BMI, body mass index; DPP-4, dipeptidyl peptidase-4.